What Documented Drug Interactions Does Tacrolimus Have, and How Serious Are They?

Tacrolimus carries multiple documented interactions with clinically serious consequences, including eight contraindicated combinations and at least two major-severity interactions requiring close monitoring. These interactions range from life-threatening hyperkalemia (dangerously elevated potassium) caused by concurrent potassium supplementation, to severe elevation of tacrolimus blood levels triggered by drugs that inhibit its metabolism, to additive immunosuppression and QT interval prolongation. This guide explains each documented interaction sourced from FDA-labeled tacrolimus information and related drug labeling, distinguishes established mechanisms from general pharmacology, and directs you to the specific monitoring and clinical decision points your pharmacist or physician should address before you begin or continue any tacrolimus-based regimen.

What Is Tacrolimus and How Does It Work?

Tacrolimus is a potent immunosuppressant medication used primarily to prevent organ rejection after transplantation and to manage certain autoimmune and inflammatory conditions. It works by suppressing T-cell activation through inhibition of the calcineurin phosphatase pathway, thereby reducing the body's immune response to a foreign organ or tissue. Because it is a narrow-therapeutic-window drug—meaning the difference between an ineffective dose and a toxic dose is relatively small—even modest increases in blood concentration can produce serious adverse effects including nephrotoxicity (kidney damage), neurotoxicity (nerve and brain damage), and cardiac arrhythmias.

Tacrolimus is metabolized primarily through the cytochrome P450 enzyme system, specifically CYP3A4 and CYP3A5. This metabolic route is clinically important because many commonly used drugs inhibit or induce these enzymes, altering how quickly tacrolimus is broken down and cleared from the body. Any change in metabolism can shift tacrolimus concentrations into the toxic range or below the therapeutic level, creating clinical risk.

Most Serious Documented Interactions: Contraindicated Combinations

The FDA-labeled tacrolimus information and related drug records document eight contraindicated combinations. These are drug pairs the source labeling explicitly recommends avoiding entirely, or managing only under close specialist supervision with rigorous monitoring if avoidance is impossible.

Potassium-Elevating Drugs (Potassium Phosphates, Potassium Chloride, and Related Formulations)

Four separate contraindicated interactions involve potassium supplementation in various formulations: potassium phosphates (unspecified form), potassium phosphate monobasic and dibasic injection, potassium phosphates in sodium chloride formulations, and (at major severity) potassium chloride. All of these combinations carry the same documented risk: severe and potentially fatal hyperkalemia—abnormally high serum potassium concentration.

Tacrolimus itself increases serum potassium as a direct effect of its immunosuppressive mechanism. When a patient simultaneously receives potassium supplementation, the two effects are additive, meaning the rise in serum potassium is greater than either drug alone would produce. Severe hyperkalemia can trigger life-threatening cardiac arrhythmias and sudden cardiac arrest.

The source records recommend avoiding potassium supplementation in patients on tacrolimus entirely. If clinical circumstances make supplementation unavoidable—for example, if a patient has documented hypokalemia from another cause and the benefit is judged to outweigh the risk—the recommendation is to monitor serum potassium concentrations closely. The records do not specify a monitoring interval in the supplied data, so this detail must be confirmed with your transplant team or nephrologist.

Grapefruit Juice

Grapefruit juice is classified as contraindicated with tacrolimus due to its action as a strong CYP3A inhibitor. Grapefruit and grapefruit juice contain natural compounds (furanocoumarins) that inhibit CYP3A4 enzyme activity in the intestinal wall and liver. Because tacrolimus depends on CYP3A for its metabolism, inhibition of this pathway causes tacrolimus blood levels to rise, sometimes dramatically. Elevated tacrolimus exposure increases the risk of serious adverse reactions including neurotoxicity and QT interval prolongation (a cardiac rhythm disturbance that can progress to dangerous arrhythmias).

The contraindicated designation means grapefruit juice should be avoided entirely during tacrolimus therapy. This prohibition applies to grapefruit juice, grapefruit fruit, and products containing grapefruit. Patients should confirm with their pharmacist whether any over-the-counter beverages or supplements contain grapefruit.

Nelfinavir (HIV Protease Inhibitor)

Nelfinavir is an HIV protease inhibitor that functions as a strong CYP3A inhibitor. Like grapefruit juice, nelfinavir blocks the enzymatic breakdown of tacrolimus, leading to increased tacrolimus concentrations and risk of serious adverse reactions. The source record states that concomitant use should be avoided. If a patient requires both an antiretroviral regimen and tacrolimus for transplant maintenance, alternative antiretroviral agents with less CYP3A inhibition should be considered in consultation with both the transplant team and infectious disease specialist.

Mifepristone (Medication Abortion Agent)

Mifepristone is a progesterone antagonist used in medication abortion and certain other applications. It inhibits CYP3A, thereby increasing tacrolimus exposure. The source record notes that mifepristone increases tacrolimus levels and that the contraindicated designation is due to tacrolimus's narrow therapeutic window. Combined use is not recommended due to the unpredictability of tacrolimus concentration elevation and the resulting risk of toxicity.

Tofacitinib (JAK Inhibitor)

Tofacitinib is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions such as rheumatoid arthritis and ulcerative colitis. The source record identifies it as an immunosuppressant that poses an additive immunosuppression risk when combined with tacrolimus. The FDA labeling for XELJANZ (tofacitinib) explicitly states that concomitant use with other immunosuppressive drugs is not recommended. The mechanism is straightforward: two immunosuppressants used together increase the cumulative suppression of immune function beyond what either drug alone would produce, raising infection risk and potentially compromising the benefit of immunosuppression in transplant patients (where some immune function is desirable to prevent opportunistic infection).

Pimozide (Antipsychotic)

Pimozide is an antipsychotic medication that has a documented effect of QT interval prolongation—a change in the heart's electrical rhythm that can progress to dangerous ventricular arrhythmias. Tacrolimus also has been documented to prolong the QT interval. When both drugs are used concurrently, the QT-prolonging effects are additive, creating a heightened arrhythmia risk. The source record designates this as contraindicated. Patients requiring an antipsychotic while on tacrolimus should discuss alternative agents with their prescriber and cardiologist.

Other Supplied Interactions to Monitor

Potassium Chloride (Major Severity)

Potassium chloride appears in the supplied interaction database as a separate major-severity interaction (distinct from the contraindicated potassium phosphate entries). Like all potassium supplements, it poses the risk of severe and potentially fatal hyperkalemia when combined with tacrolimus's intrinsic potassium-elevating effect. This record does not specify a mechanism beyond the additive potassium increase but confirms the same clinical risk. The designation as major (rather than contraindicated, like the phosphate formulations) may reflect differing source record conventions, but the clinical guidance remains consistent: avoid concurrent use, or monitor serum potassium closely if avoidance is not possible.

Fenofibric Acid (Fibrate Lipid-Lowering Drug, Major Severity)

Fenofibric acid is a fibrate used to lower triglyceride levels. The documented interaction addresses two overlapping mechanisms: tacrolimus can cause nephrotoxicity (direct kidney damage) and can reduce creatinine clearance (a measure of kidney filtration capacity). Fibrate drugs, including fenofibric acid, depend on renal filtration for clearance from the body. When tacrolimus-induced kidney dysfunction reduces the rate at which fenofibric acid is cleared, fenofibric acid concentrations may rise, increasing the risk of fibrate-related adverse effects including muscle breakdown (rhabdomyolysis) and worsening kidney function—creating a vicious cycle of declining renal function.

The source record recommends monitoring renal function and using the lowest effective dosage of both drugs. It does not specify a monitoring frequency or suggest dose reductions in the supplied data; these clinical decisions should be made in consultation with your nephrologist and prescribing physician. Renal function monitoring typically involves periodic measurement of serum creatinine and estimated glomerular filtration rate (eGFR), but the appropriate interval depends on your individual clinical status.

Explaining the Interaction Mechanisms

Several of the documented interactions share common mechanisms, which helps explain why multiple drug classes and individual agents are contraindicated with tacrolimus.

CYP3A Inhibition

Three contraindicated interactions (grapefruit juice, nelfinavir, and mifepristone) work through CYP3A enzyme inhibition. Tacrolimus is metabolized almost exclusively by CYP3A4 and CYP3A5. When a co-administered drug inhibits these enzymes, tacrolimus is metabolized more slowly, allowing it to accumulate in the bloodstream. Because tacrolimus has a narrow therapeutic window, even a moderate increase in concentration—perhaps 30% or 40% above the target level—can produce toxicity. CYP3A inhibition is particularly dangerous with tacrolimus because the degree of enzyme inhibition varies among individuals and can be difficult to predict from dose alone.

Additive Potassium Elevation

Four of the contraindicated interactions and one major-severity interaction involve potassium supplementation. Tacrolimus raises serum potassium through its effect on the renin-angiotensin-aldosterone system and through effects on renal potassium handling. The exact mechanism is not fully specified in the supplied records but is well established in transplant pharmacology. When an external potassium source is added, the body's potassium burden increases beyond what tacrolimus alone produces. In patients with any degree of renal impairment (common in transplant recipients), the kidneys may not excrete the excess potassium efficiently, leading to severe hyperkalemia.

Additive Immunosuppression

Tofacitinib, a JAK inhibitor, is documented as contraindicated because it produces additional immunosuppression beyond tacrolimus's effect. This differs from the toxicity-focused interactions above: rather than raising drug levels or causing an overdose effect, combining two immunosuppressants simply intensifies the intended therapeutic effect—immune suppression—to a degree that may increase infection risk without proportional transplant benefit.

Additive QT Prolongation

Pimozide and tacrolimus both prolong the QT interval, an electrical property of the heart muscle. When both drugs are present, the QT interval lengthens more than either drug alone would cause. Prolonged QT intervals can trigger torsades de pointes, a specific type of ventricular arrhythmia that is sometimes self-limited but can degenerate into ventricular fibrillation and cardiac arrest.

Nephrotoxicity and Reduced Renal Clearance

Tacrolimus's documented potential to impair kidney function creates a compounding risk when combined with drugs dependent on renal excretion. Fenofibric acid illustrates this: as tacrolimus-induced kidney damage reduces glomerular filtration, fenofibric acid clears more slowly, concentrations rise, and the fibrate itself may worsen kidney function further. This mechanism is most relevant for elderly patients, patients with baseline kidney disease, and patients on multiple nephrotoxic agents.

Hypothetical Clinical Scenarios

Scenario 1: Transplant Patient on Tacrolimus Who Develops High Potassium Levels

Imagine a kidney transplant recipient stable on tacrolimus with normal kidney function who develops muscle weakness and fatigue. Blood work shows serum potassium of 6.2 mEq/L (normal is approximately 3.5–5.0). The patient reports having started a potassium supplement recommended by a primary care provider for general health. In this hypothetical case, the documented contraindicated interaction between tacrolimus and potassium phosphates (or chloride) is realized: the two drugs' additive potassium-raising effects have produced dangerous hyperkalemia. The pharmacist or physician would likely recommend stopping the potassium supplement immediately and rechecking potassium within hours or days, depending on the severity. This scenario illustrates why all potassium supplementation should be discussed with the transplant team before initiation.

Scenario 2: HIV-Positive Transplant Patient Requiring Protease Inhibitor Therapy

Consider an organ transplant recipient who is also HIV-positive and on tacrolimus-based immunosuppression. The patient's HIV regimen previously included nelfinavir, a protease inhibitor. The documented CYP3A inhibition interaction means that nelfinavir would cause tacrolimus levels to rise, potentially into the toxic range, risking nephrotoxicity and neurotoxicity. In this hypothetical situation, the transplant and infectious disease teams would need to collaborate to either switch the HIV regimen to agents with minimal CYP3A inhibition or, if nelfinavir is essential, to reduce the tacrolimus dose substantially and monitor tacrolimus levels very frequently. This scenario highlights why transplant patients requiring multiple complex medications must have coordinated care among multiple specialists.

Documented Contraindicated and Major-Severity Interactions at a Glance

• Potassium Phosphates (multiple formulations) — Contraindicated; risk of severe and potentially fatal hyperkalemia through additive potassium-increasing effects.
• Grapefruit Juice — Contraindicated; CYP3A inhibition increases tacrolimus concentrations, raising neurotoxicity and QT prolongation risk.
• Nelfinavir (HIV Protease Inhibitor) — Contraindicated; CYP3A inhibition increases tacrolimus concentrations and serious adverse reaction risk.
• Mifepristone — Contraindicated; CYP3A inhibition increases tacrolimus exposure; narrow therapeutic window makes this combination unacceptable.
• Tofacitinib (JAK Inhibitor) — Contraindicated; additive immunosuppression not recommended per FDA labeling.
• Pimozide (Antipsychotic) — Contraindicated; additive QT interval prolongation increases ventricular arrhythmia risk.
• Potassium Chloride — Major severity; risk of severe and potentially fatal hyperkalemia through additive potassium increase.
• Fenofibric Acid (Fibrate) — Major severity; tacrolimus-induced nephrotoxicity and reduced renal clearance increase fibrate toxicity risk; monitor renal function and use lowest effective doses.

Questions to Ask Your Pharmacist or Physician

Before starting or continuing tacrolimus, and before adding any new medication, ask your healthcare team:

• Does my current medication list include any of the contraindicated combinations listed here, and if so, what alternative is available?
• Am I taking any potassium supplements or over-the-counter products containing potassium, and do they need to be stopped?
• Should I avoid grapefruit and grapefruit juice entirely while on tacrolimus?
• How often should my serum potassium, kidney function, and tacrolimus blood levels be monitored?
• If I need to start a new medication (such as an antipsychotic, HIV drug, lipid-lowering agent, or any CYP3A inhibitor), how should we coordinate that with my tacrolimus therapy?
• Are there any over-the-counter supplements or herbal products that might interact with tacrolimus?
• What symptoms—such as weakness, irregular heartbeat, confusion, tremor, or changes in urine output—should prompt me to contact you urgently?

Key Takeaways

• Tacrolimus has eight documented contraindicated drug combinations and at least two major-severity interactions, all of which carry serious or potentially fatal risks.
• Potassium supplementation in any form (phosphates, chloride) is contraindicated due to the synergistic risk of severe hyperkalemia; all potassium supplements should be discussed with your transplant team before use.
• Strong CYP3A inhibitors including grapefruit juice, nelfinavir, and mifepristone are contraindicated because they elevate tacrolimus blood levels, raising the risk of neurotoxicity, QT prolongation, and other serious adverse effects.
• Tofacitinib and other immunosuppressants are contraindicated in combination with tacrolimus due to excessive immune suppression; pimozide is contraindicated due to additive QT prolongation.
• Fenofibric acid and other drugs dependent on renal excretion require careful monitoring when combined with tacrolimus because tacrolimus-induced kidney damage slows drug clearance and may worsen renal function.

Sources

• DailyMed: NLM Drug Labeling Resource — Source for FDA-labeled tacrolimus and related drug information.
• RxNorm: Normalized Naming System for Clinical Drugs — NLM source for drug nomenclature and interaction documentation.
• OpenFDA: Public FDA Data Repository — FDA-sourced adverse event and drug labeling data.
• PubMed Central — Peer-reviewed clinical literature on tacrolimus pharmacokinetics and interactions (for general background; source records in this guide are from FDA/NLM labeling).

Next Steps: Check Your Medication List at checkdruginteractions.com

This guide summarizes the documented interactions between tacrolimus and eight contraindicated drug classes and formulations, as well as major-severity interactions with potassium chloride and fenofibric acid. However, your complete medication picture—including over-the-counter drugs, supplements, and herbal products—may contain additional interactions or individual factors that only a pharmacist or physician can assess. Visit checkdruginteractions.com to enter your full medication list and receive a comprehensive interaction report tailored to your regimen. Then schedule a medication review with your pharmacist or transplant physician to discuss any interactions found and confirm that all your current medications are safe and necessary. Do not start, stop, skip, or change any medication without discussing it with your prescriber or pharmacist first, particularly when tacrolimus is involved due to its narrow therapeutic window and serious risks of both under- and over-dosing.